Amylyx Pharmaceuticals, Inc. AMLX Cash Flow Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| -$144.74M+52.0% | -$301.74M-712% | $49.27M+125% | -$198.38M-126% | ||
| $525K-41.9% | $904K-16.9% | $1.09M+123% | $487K+837% | ||
| $27.65M-16.3% | $33.04M-11.1% | $37.16M+71.1% | $21.71M+592% | ||
| —— | -$20.57M— | —— | —— | ||
| —— | -$59.81M— | —— | —— | ||
| —— | —— | —— | —— | ||
| $169K+118% | -$958K— | —— | —— | ||
| -$1.19M+47.5% | -$2.26M-10.5% | -$2.04M-123% | -$917K— | ||
| -$123.34M+26.4% | -$167.65M-1,507% | $11.92M+107% | -$179.87M-140% | ||
| $138K— | —— | $1.24M-50.9% | $2.53M+616% | ||
| $231.82M— | —— | $300.83M-27.7% | $415.87M+748% | ||
| —— | $75.65M— | —— | —— | ||
| —— | —— | —— | —— | ||
| —— | $348K-90.2% | $3.54M— | —— | ||
| $1.07M+345% | -$438K— | —— | —— | ||
| $148.8M+252% | -$97.64M— | —— | —— | ||
| $5.53M-43.9% | $9.86M-0.8% | $9.94M+383% | $2.06M— | ||
| —— | —— | —— | —— | ||
| $525K-41.9% | $904K-16.9% | $1.09M+123% | $487K+837% | ||
| $1.98M+392% | -$677K— | —— | —— | ||
| -$1.19M+47.5% | -$2.26M-10.5% | -$2.04M-123% | -$917K— | ||
| $1.73M-11.5% | $1.95M+8.6% | $1.8M+10.0% | $1.64M— | ||
| —— | —— | —— | —— | ||
| —— | —— | —— | —— | ||
| $169K+118% | -$958K— | —— | —— | ||
| —— | —— | —— | —— | ||
| $4.08M+91.2% | $2.13M-69.5% | $6.99M— | —— | ||
| $3.36M+88.4% | $1.78M-46.2% | $3.32M— | —— | ||
| -$1.19M+47.5% | -$2.26M-10.5% | -$2.04M-123% | -$917K— | ||
| -$123.48M+26.4% | -$167.8M-1,671% | $10.68M+106% | -$182.4M-143% | ||
| -$123.48M+26.4% | -$167.8M-1,671% | $10.68M+106% | -$182.4M-143% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Amylyx Pharmaceuticals, Inc.'s cash flow data come from?
- Every line is extracted from Amylyx Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.